Clinical and Molecular Hepatology (Clin Mol Hepatol, CMH)

Editorial

Long-term prognosis and management of hepatocellular carcinoma after curative treatment

Naoshi Nishida

Clin Mol Hepatol. 2020;26(4):480-483. Published online September 21, 2020

DOI: https://doi.org/10.3350/cmh.2020.0208

View: 5106 Download: 97 Web of Science: 11 Crossref: 11

Sarcopenia and blood myokine levels as prognostic biomarkers in patients with liver cirrhosis or hepatocellular carcinoma

Sooyeon Oh, Jooho Lee

Clin Mol Hepatol. 2020;26(4):476-479. Published online October 1, 2020

DOI: https://doi.org/10.3350/cmh.2020.0192

View: 4706 Download: 148 Web of Science: 12 Crossref: 11

Review

Precision medicine in nonalcoholic fatty liver disease: New therapeutic insights from genetics and systems biology

Silvia Sookoian, Carlos J. Pirola

Clin Mol Hepatol. 2020;26(4):461-475. Published online September 10, 2020

DOI: https://doi.org/10.3350/cmh.2020.0136

View: 8235 Download: 276 Web of Science: 35 Crossref: 37

Beneficial effect of anti-diabetic drugs for nonalcoholic fatty liver disease

Kyung-Soo Kim, Byung-Wan Lee

Clin Mol Hepatol. 2020;26(4):430-443. Published online August 14, 2020

DOI: https://doi.org/10.3350/cmh.2020.0137

View: 9710 Download: 476 Web of Science: 35 Crossref: 35

Evidence-based clinical advice for nutrition and dietary weight loss strategies for the management of NAFLD and NASH

Theresa J. Hydes, Sujan Ravi, Rohit Loomba, Meagan E. Gray

Clin Mol Hepatol. 2020;26(4):383-400. Published online July 17, 2020

DOI: https://doi.org/10.3350/cmh.2020.0067

View: 10146 Download: 511 Web of Science: 46 Crossref: 48

Original Article

Low-level viremia and cirrhotic complications in patients with chronic hepatitis B according to adherence to entecavir

Seung Bum Lee, Joonho Jeong, Jae Ho Park, Seok Won Jung, In Du Jeong, Sung-Jo Bang, Jung Woo Shin, Bo Ryung Park, Eun Ji Park, Neung Hwa Park

Clin Mol Hepatol. 2020;26(3):364-375. Published online May 29, 2020

DOI: https://doi.org/10.3350/cmh.2020.0012

View: 5834 Download: 269 Web of Science: 24 Crossref: 21

Entecavir+tenofovir vs. lamivudine/telbivudine+adefovir in chronic hepatitis B patients with prior suboptimal response

Hyun Young Woo, Jun Yong Park, Si Hyun Bae, Chang Wook Kim, Jae Young Jang, Won Young Tak, Dong Joon Kim, In Hee Kim, Jeong Heo, Sang Hoon Ahn

Clin Mol Hepatol. 2020;26(3):352-363. Published online May 28, 2020

DOI: https://doi.org/10.3350/cmh.2019.0044n

View: 4807 Download: 183 Web of Science: 3 Crossref: 5

Comparison of LI-RADS 2018 and KLCA-NCC 2018 for noninvasive diagnosis of hepatocellular carcinoma using magnetic resonance imaging

Sunyoung Lee, Seung-seob Kim, Dong ryul Chang, Hyerim Kim, Myeong-Jin Kim

Clin Mol Hepatol. 2020;26(3):340-351. Published online June 4, 2020

DOI: https://doi.org/10.3350/cmh.2020.0004

View: 8500 Download: 205 Web of Science: 42 Crossref: 46

Editorial

Low-level viremia in patients undergoing antiviral therapy: Does it indicate time for a change?

Jung Hee Kim, Dong Hyun Sinn

Clin Mol Hepatol. 2020;26(3):315-317. Published online June 23, 2020

DOI: https://doi.org/10.3350/cmh.2020.0084

View: 4597 Download: 104 Crossref: 1

Is tenofovir and entecavir combination therapy still the optimal treatment for chronic hepatitis B patients with prior suboptimal response?

Byoung Kuk Jang

Clin Mol Hepatol. 2020;26(3):312-314. Published online July 1, 2020

DOI: https://doi.org/10.3350/cmh.2020.0099

View: 4911 Download: 119 Crossref: 2

Diagnosis of hepatocellular carcinoma: Which MRI contrast agent? Which diagnostic criteria?

So Yeon Kim

Clin Mol Hepatol. 2020;26(3):309-311. Published online June 15, 2020

DOI: https://doi.org/10.3350/cmh.2020.0061

View: 4737 Download: 99 Web of Science: 5 Crossref: 5

Optimal sequence of systemic therapy after sorafenib failure in patients with hepatocellular carcinoma

Sojung Han, Do Young Kim

Clin Mol Hepatol. 2020;26(3):305-308. Published online July 1, 2020

DOI: https://doi.org/10.3350/cmh.2020.0096

View: 4196 Download: 108 Web of Science: 5 Crossref: 5

Special Topic

Management of liver diseases during the pandemic of coronavirus disease-19

Ju-Yeon Cho, Soon Sun Kim, Young-Sun Lee, Do Seon Song, Jeong-Hoon Lee, Ji Hoon Kim

Clin Mol Hepatol. 2020;26(3):243-250. Published online June 23, 2020

DOI: https://doi.org/10.3350/cmh.2020.0111

View: 7054 Download: 231 Web of Science: 8 Crossref: 7

Original Article

Limited expression of TLR9 on T cells and its functional consequences in patients with nonalcoholic fatty liver disease

Nadia Soledad Alegre, Cecilia Claudia Garcia, Luis Ariel Billordo, Beatriz Ameigeiras, Daniel Poncino, Javier Benavides, Luis Colombato, Alejandra Claudia Cherñavsky

Clin Mol Hepatol. 2020;26(2):216-226. Published online December 5, 2019

DOI: https://doi.org/10.3350/cmh.2019.0074

View: 6578 Download: 140 Web of Science: 14 Crossref: 12

Trends in the prevalence of chronic liver disease in the Korean adult population, 1998–2017

Seung Ha Park, Lindsay D. Plank, Ki Tae Suk, Yong Eun Park, Jin Lee, Joon Hyuk Choi, Nae Yun Heo, Jongha Park, Tae Oh Kim, Young Soo Moon, Hyun Kuk Kim, Hang Jea Jang, Ha Young Park, Dong Joon Kim

Clin Mol Hepatol. 2020;26(2):209-215. Published online November 4, 2019

DOI: https://doi.org/10.3350/cmh.2019.0065

View: 33812 Download: 403 Web of Science: 76 Crossref: 79

Comparisons between non-alcoholic steatohepatitis and alcohol-related hepatocellular carcinoma

Rahul Kumar, Boon-Bee George Goh, Jia-Wen Kam, Pik-Eu Chang, Chee-Kiat Tan

Clin Mol Hepatol. 2020;26(2):196-208. Published online January 9, 2020

DOI: https://doi.org/10.3350/cmh.2019.0012

View: 8044 Download: 269 Web of Science: 14 Crossref: 14

Editorial

Toll-like receptor 9, a possible blocker of non-alcoholic steatohepatitis?

Soung Won Jeong

Clin Mol Hepatol. 2020;26(2):185-186. Published online March 23, 2020

DOI: https://doi.org/10.3350/cmh.2020.0046

View: 4343 Download: 87 Web of Science: 1 Crossref: 1

Should you advocate for hepatocellular carcinoma surveillance in patients with alcohol-related liver disease or non-alcoholic fatty liver disease?

Ju Hyun Shim

Clin Mol Hepatol. 2020;26(2):183-184. Published online March 12, 2020

DOI: https://doi.org/10.3350/cmh.2020.0042

View: 4212 Download: 111 Web of Science: 6 Crossref: 6

Review

Switching to systemic therapy after locoregional treatment failure: Definition and best timing

Sadahisa Ogasawara, Yoshihiko Ooka, Keisuke Koroki, Susumu Maruta, Hiroaki Kanzaki, Kengo Kanayama, Kazufumi Kobayashi, Soichiro Kiyono, Masato Nakamura, Naoya Kanogawa, Tomoko Saito, Takayuki Kondo, Eiichiro Suzuki, Shingo Nakamoto, Akinobu Tawada, Tetsuhiro Chiba, Makoto Arai, Jun Kato, Naoya Kato

Clin Mol Hepatol. 2020;26(2):155-162. Published online January 15, 2020

DOI: https://doi.org/10.3350/cmh.2019.0021n

View: 9781 Download: 408 Web of Science: 41 Crossref: 38

Application of transient elastography in nonalcoholic fatty liver disease

Xinrong Zhang, Grace Lai-Hung Wong, Vincent Wai-Sun Wong

Clin Mol Hepatol. 2020;26(2):128-141. Published online November 8, 2019

DOI: https://doi.org/10.3350/cmh.2019.0001n

View: 13918 Download: 561 Web of Science: 59 Crossref: 63

Original Article

Vimentin as a potential therapeutic target in sorafenib resistant HepG2, a HCC model cell line

Ankita Makol, Harpreet Kaur, Sakshi Sharma, Shruthi Kanthaje, Ramanpreet Kaur, Anuradha Chakraborti

Clin Mol Hepatol. 2020;26(1):45-53. Published online September 30, 2019

DOI: https://doi.org/10.3350/cmh.2019.0031

View: 7664 Download: 250 Web of Science: 17 Crossref: 14

Serum Wisteria floribunda agglutinin-positive human Mac-2 binding protein level predicts recurrence of hepatitis B virus-related hepatocellular carcinoma after curative resection

Hye Soo Kim, Seung Up Kim, Beom Kyung Kim, Jun Yong Park, Do Young Kim, Sang Hoon Ahn, Kwang-Hyub Han, Young Nyun Park, Dai Hoon Han, Kyung Sik Kim, Jin Sub Choi, Gi Hong Choi, Hyon-Suk Kim

Clin Mol Hepatol. 2020;26(1):33-44. Published online June 27, 2019

DOI: https://doi.org/10.3350/cmh.2018.0073

View: 5863 Download: 185 Web of Science: 18 Crossref: 15

A survey on transarterial chemoembolization refractoriness and a real-world treatment pattern for hepatocellular carcinoma in Korea

Jae Seung Lee, Beom Kyung Kim, Seung Up Kim, Jun Yong Park, Sang Hoon Ahn, Jin Sil Seong, Kwang-Hyub Han, Do Young Kim

Clin Mol Hepatol. 2020;26(1):24-32. Published online May 20, 2019

DOI: https://doi.org/10.3350/cmh.2018.0065

View: 9640 Download: 299 Web of Science: 29 Crossref: 29

Review

The fibrogenic process and the unleashing of acute-on-chronic liver failure

Guillermo Nahúm López-Sánchez, Mayra Dóminguez-Pérez, Misael Uribe, Natalia Nuño-Lámbarri

Clin Mol Hepatol. 2020;26(1):7-15. Published online June 14, 2019

DOI: https://doi.org/10.3350/cmh.2019.0011

View: 11330 Download: 365 Web of Science: 9 Crossref: 11

Immunologic strategies and outcomes in ABO-incompatible living donor liver transplantation

Jongwook Oh, Jong Man Kim

Clin Mol Hepatol. 2020;26(1):1-6. Published online March 26, 2019

DOI: https://doi.org/10.3350/cmh.2019.0023

View: 15573 Download: 608 Web of Science: 22 Crossref: 23

Original Article

Risk assessment of hepatocellular carcinoma development for indeterminate hepatic nodules in patients with chronic hepatitis B

Haneulsaem Shin, Yeon Woo Jung, Beom Kyung Kim, Jun Yong Park, Do Young Kim, Sang Hoon Ahn, Kwang-Hyub Han, Yeun-Yoon Kim, Jin-Young Choi, Seung Up Kim

Clin Mol Hepatol. 2019;25(4):390-399. Published online May 31, 2019

DOI: https://doi.org/10.3350/cmh.2018.0103

View: 6137 Download: 145 Web of Science: 19 Crossref: 19

Bi-monthly hepatic arterial infusion chemotherapy as a novel strategy for advanced hepatocellular carcinoma in decompensated cirrhotic patients

Kei Moriya, Tadashi Namisaki, Shinya Sato, Masanori Furukawa, Akitoshi Douhara, Hideto Kawaratani, Kosuke Kaji, Naotaka Shimozato, Yasuhiko Sawada, Soichiro Saikawa, Hiroaki Takaya, Koh Kitagawa, Takemi Akahane, Akira Mitoro, Junichi Yamao, Hitoshi Yoshiji

Clin Mol Hepatol. 2019;25(4):381-389. Published online August 13, 2019

DOI: https://doi.org/10.3350/cmh.2019.0037

View: 5512 Download: 136 Web of Science: 12 Crossref: 10

Incidence and risk factors of dysphagia after variceal band ligation

Saraswathi Arasu, Hammad Liaquat, Jaspreet Suri, Adam C. Ehrlich, Frank K. Friedenberg

Clin Mol Hepatol. 2019;25(4):374-380. Published online July 18, 2019

DOI: https://doi.org/10.3350/cmh.2019.0019

View: 6077 Download: 180 Web of Science: 1 Crossref: 1

Review

Appropriate treatment modality for solitary small hepatocellular carcinoma: Radiofrequency ablation vs. resection vs. transplantation?

Keun Soo Ahn, Koo Jeong Kang

Clin Mol Hepatol. 2019;25(4):354-359. Published online April 22, 2019

DOI: https://doi.org/10.3350/cmh.2018.0096

View: 7609 Download: 359 Web of Science: 41 Crossref: 39

Ultraselective conventional transarterial chemoembolization: When and how?

Shiro Miyayama

Clin Mol Hepatol. 2019;25(4):344-353. Published online April 26, 2019

DOI: https://doi.org/10.3350/cmh.2019.0016

View: 11100 Download: 548 Web of Science: 28 Crossref: 31

1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10 | Next

Viewed By 5583	Prognostic value of ultra-low-pass whole-genome sequencing of circulating tumor DNA in hepatocellular carcinoma under systemic treatment
Viewed By 4787	MAFLD: How is it different from NAFLD?
Viewed By 4526	Assessing the performance of ChatGPT in answering questions regarding cirrhosis and hepatocellular carcinoma
Viewed By 3696	2022 KLCA-NCC Korea practice guidelines for the management of hepatocellular carcinoma
Viewed By 3675	Global incidence and prevalence of nonalcoholic fatty liver disease

Cited By 135	Assessing the performance of ChatGPT in answering questions regarding cirrhosis and hepatocellular carcinoma
Cited By 103	2022 KLCA-NCC Korea practice guidelines for the management of hepatocellular carcinoma
Cited By 80	Global incidence and prevalence of nonalcoholic fatty liver disease
Cited By 68	Forecasted 2040 global prevalence of nonalcoholic fatty liver disease using hierarchical bayesian approach
Cited By 57	MAFLD: How is it different from NAFLD?

Search